CareDx, Inc. is a precision medicine company providing non-invasive molecular testing, laboratory products, digital health technologies, and patient solutions for transplant patients. The company serves clinicians and transplant centers in the United States and Europe, focusing on heart, kidney, and lung transplants, as well as hematopoietic stem cell and cell therapy recipients. Its portfolio includes AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung, which utilize donor-derived cell-free DNA and gene expression profiling to monitor organ health and rejection. CareDx also offers pre-transplant matching products, digital workflow and list management software, and specialized pharmacy services for medication management. The company partners with pharmaceutical and biopharmaceutical firms for clinical trials and patient screening. Incorporated in 1998 as Hippocratic Engineering, Inc., the company changed its name to BioCardia, Inc. in 1999, Expression Diagnostics, Inc. in 2002, XDx, Inc. in 2007, and CareDx, Inc. in 2014. It operates as a single reportable segment with primary operations in California, Nebraska, and Sweden.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Diagnostics & Research Homepage caredxinc.com
Sector Healthcare IR page investors.caredxinc.com
Tags
molecular diagnostics, transplant medicine, genomics, cell-free dna, gene expression profiling, digital health, pharmacy services, solid organ transplant, stem cell transplant, AlloSure Kidney, AlloMap Heart, AlloSure Heart, AlloSure Lung
Press page —

Metrics

Valuation  
Market cap $ 3.957B
Market cap (USD) $ 3.957B
P/E 31.56
PEG —
P/BV 8.47
P/S 7.96
P/OCF 57.34
P/FCF 111.65
Dividend yield 0.36%
Turnover / mcap —
Returns  
ROE -6.3%
ROI -8.3%
ROIC -9.0%
Profit margin -5.6%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock Yes
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 37
Quality score -47.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 379.805M 333.785M 280.324M 321.793M 296.397M 192.194M 127.068M 76.569M 48.324M 40.631M 28.144M 27.306M 22.098M
Net profit -21.354M 52.549M -190.284M -76.613M -30.662M -18.714M -21.968M -46.756M -55.469M -39.469M -13.707M 781K -3.542M
Free cash flow 35.444M 31.564M -27.628M -49.573M -39.553M — — -6.042M -14.493M -17.072M -10.951M -4.083M -644K

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 18.84 21.41 12 11.41 45.48 72.45 21.57 25.14 7.34 2.7 6.4 7.25 —
Price performance 12m -0.12 0.78 0.05 -0.75 -0.37 2.36 -0.14 2.43 1.72 -0.58 -0.12 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 2.77M 2.99M 9.76M 24.1M 34.6M 59.8M 66.3M 51.1M 64.6M 42.6M
↳ YoY growth +8.1% +226.3% +146.5% +43.9% +72.6% +11.0% -23.0% +26.5% -34.0%
↳ 5y CAGR +84.9% +85.8% +39.2% +21.8% +4.2%
Borrowings, current (USD) 22.8M 15.7M 0.00 0.00 0.00 — — — — —
Borrowings, non-current (USD) 1.1M 18.3M 0.00 0.00 0.00 — — — — —
Lease liabilities (USD) — — 172,000 3.02M 18.1M 21.4M 39M 34.2M 28.4M 26.2M
Cash and deposits (USD) 17.3M 16.9M 64.6M 38.2M 135M 348M 89.9M 82.2M 115M 65.4M
Intangible assets (USD) 33.1M 33.1M 33.3M 45.5M 44.4M 50.2M 43.1M 45.7M 38.2M 32M
Right-of-use assets (USD) — — 0.00 4.73M 15.2M 18M 34.7M 29.9M 24.3M 22.8M
Net debt (borrowings + leases - cash) (USD) 6.69M 17.2M -64.6M -35.2M -117M — — — — —
Cash flow detail
Operating cash flow (USD) -16.5M -14.3M -4.01M -2.77M 33.4M -19.3M -25.2M -18.4M 38M 42M
Purchases of property, plant and equipment (USD) -549,000 -186,000 -2.04M — — — — — — —
Purchases of intangible assets (USD) 0.00 0.00 -5.2M -1.15M -3.25M -6.7M -3.1M -896,000 0.00 -675,000
Change in receivables (cash effect) (USD) 1.05M -109,000 -3.97M -12.7M -10.4M -24.4M -6.66M 16M -13.7M 22.5M
Change in inventories (cash effect) (USD) 492,000 1.03M 363,000 -1.27M -3.2M -6.93M -2.86M 54,000 -1.02M -4.96M
Change in payables (cash effect) (USD) -620,000 292,000 -168,000 — — — — — — —
Share buybacks (cash effect) (USD) — — — — 0.00 0.00 -642,000 -27.5M -522,000 -87.8M
Interest paid (cash effect) (USD) -867,000 -3.27M -1.77M -22,000 -10,000 -1,000 -8,000 0.00 0.00 —
Income taxes paid (cash effect) (USD) — — 0.00 0.00 -80,000 -14,000 -392,000 -738,000 -317,000 -284,000
Share-based compensation (USD) 2M 1.74M 7.14M 22.4M 23.4M 36.1M 46.6M 49.1M 66.4M 34.9M
Operating cash flow before change in receivables (USD) -17.6M -14.2M -40,000 9.91M 43.8M 5.12M -18.6M -34.4M 51.8M 19.5M
Free cash flow (OCF - PPE - intangibles) (USD) -17.1M -14.5M -11.2M — — — — — — —
Income detail
Research and development expense (USD) 12.4M 12.4M 14.5M 30.7M 48.9M 76.5M 90.4M 81.9M 72.4M 71.4M
↳ 5y CAGR +21.1% +35.5% +51.5% +39.3% +43.9% +48.8% +41.3% +18.7% +7.9%
Total comprehensive income (USD) -43.5M -54.3M -48.7M -22.9M -15.6M -33.2M -79.4M -190M 50.9M -18.3M
Comprehensive income to owners (USD) -43.1M -54.2M -48.7M -22.9M -15.6M -33.2M -79.4M -190M 50.9M -18.3M
Reported Mar 6, 2019 Mar 6, 2019 Feb 24, 2021 Feb 24, 2021 Feb 27, 2023 Feb 27, 2023 Feb 27, 2023 Feb 28, 2024 Feb 28, 2025 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Third Quarter Revenue Growth of 39% to $139 Million

Raises 2026 Revenue Guidance to $520 Million to $530 Million and Adjusted EBITDA Guidance to $90 Million to $100 Million

BRISBANE, Calif. — (BUSINESS WIRE) — CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 Financial Highlights

• Revenue of $139 million, an increase of 39% year-over-year

• Testing Services revenue of $119 million, an increase of 65% year-over-year

• Testing Services volume of approximately 75,900, an increase of 51% year-over-year, including contributions following our acquisition of NavDx

• Patient and Digital Solutions revenue of $20 million, an increase of 31% year-over-year

• GAAP net income of $19 million, compared with GAAP net income of $2 million for the third quarter of 2025

• Closed the acquisition of Naveris, Inc.

Second Quarter Revenue Growth of 52% to $132 Million

Raises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66 Million to $78 Million

BRISBANE, Calif. — (BUSINESS WIRE) — CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 Financial Highlights

• Revenue of $132 million, an increase of 52% year-over-year

• Testing Services revenue of $100 million, an increase of 61% year-over-year, and Testing Services volume of approximately 58,000, an increase of 17% year-over-year

• Patient and Digital Solutions revenue of $19 million and Lab Product revenue of $13 million, representing year-over-year growth of 50% and 8%, respectively

• Average revenue per test of approximately $1,720, including $16 million in prior period revenue

• GAAP net income of $111 million, compared to GAAP net loss of $9 million for the second quarter of 2025

• Closed the sale of the Lab Products business on June 30, recognizing a $113 million gain on sale included in GAAP operating income and e

On July 7, 2026, CareDx, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) with the Securities and Exchange Commission (the “SEC”) reporting the completion of its acquisition of Naveris, Inc., a Delaware corporation (“Naveris”). In order to comply with the rules and regulations promulgated by the SEC under the Securities Exchange Act of 1934, as amended, and the Securities Act of 1933, as amended, the Company hereby amends Item 9.01 of the Original 8-K for the purpose of filing the historical financial statements of Naveris and the related pro forma financial information in accordance with Article 11 of Regulation S-X, which were not previously filed with the Original 8-K. This amendment should be read in conjunction with the Original 8-K. Except as set forth herein, no modifications have been made to the information contained in the Original 8-K, and the Company has not updated any information contained therein to reflect events that have occurred since the date of the Original 8-K.

Prompts

CareDx, Inc. (ticker CDNA), listed in United States.

Company History

Date Change Detail
Mar 31, 2014 Renamed XDx, Inc. → CAREDX, INC.

ETFs Holding CareDx, Inc.

ETF Weight in ETF Shares Market value As of
ARKG 3.71% 906,349 $ 67.577M Nov 18, 2026
BRNY 1.85% 137,564 $ 10.26M Nov 18, 2026
SAWS 1.43% 2,554 $ 111.635K Jul 31, 2026
BRES 1.13% 92,550 $ 6.9M Nov 18, 2026
JSML 1.07% 88,521 $ 3.869M Jul 31, 2026
JSMD 0.95% 229,825 $ 10.046M Jul 31, 2026
HELX 0.82% 8,000 $ 228K Jun 30, 2026
LITL 0.46% 352 $ 26.245K Nov 17, 2026
RUSC 0.28% 7,900 $ 225.15K Jun 30, 2026
AVSC 0.26% 111,368 $ 8.21M Nov 16, 2026
SEIS 0.20% 40,262 $ 1.147M Jun 30, 2026
VFMF 0.18% 36,001 $ 1.804M Aug 31, 2026
FSEG 0.11% 225 $ 6,412.50 Jun 30, 2026
FESM 0.11% 216,571 $ 6.172M Jun 30, 2026
DFAS 0.09% 388,358 $ 30.995M Nov 12, 2026
VFMO 0.09% 34,662 $ 1.737M Aug 31, 2026
PSC 0.09% 70,167 $ 2M Jun 30, 2026
VFQY 0.06% 6,435 $ 322.458K Aug 31, 2026
RESM 0.04% 54 $ 1,539.00 Jun 30, 2026
DFAC 0.02% 221,690 $ 17.693M Nov 12, 2026
DFSU 0.02% 4,575 $ 365.131K Nov 12, 2026
MSSM 0.01% 2,033 $ 101.874K Aug 31, 2026
AVUS 0.01% 10,339 $ 762.191K Nov 16, 2026
DCOR 0.01% 40,482 $ 3.231M Nov 12, 2026
DFAU 0.01% 10,349 $ 825.954K Nov 12, 2026
DFUV 0.01% 12,213 $ 974.72K Nov 12, 2026
DFUS 0.00% 13,194 $ 1.053M Nov 12, 2026
DXUV 0.00% 710 $ 56.665K Nov 12, 2026
EBI 0.00% 22 $ 1,102.42 Aug 31, 2026
AVSU 0.00% 304 $ 22.411K Nov 16, 2026